Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Okuno

Showing results (211-220 of 230) with videos related to

Pageof 23
Sort By:
Advanced Materials (Deerfield Beach, Fla.)|September 19, 2025
Terahertz Electronic and Spin Currents in Wafer-Scale Van der Waals Bi<sub>2</sub>Se<sub>3</sub>/WSe<sub>2</sub> Heterostructures and PolymorphsM Mičica, A Wright, S Massabeau, et al.
The Oncologist|July 24, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 StudyRichard F Riedel, Karla V Ballman, Yao Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2011
Quality of life and symptom burden among long-term lung cancer survivorsPing Yang, Andrea L Cheville, Jason A Wampfler, et al.
Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to PembrolizumabEmily Z Keung, Melissa Burgess, Ruth Salazar, et al.
The Lancet. Oncology|October 10, 2017
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialHussein A Tawbi, Melissa Burgess, Vanessa Bolejack, et al.
Mayo Clinic Proceedings|June 26, 2019
Oncolytic Measles Virotherapy and Opposition to Measles VaccinationStephen J Russell, Dusica Babovic-Vuksanovic, Alice Bexon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2023
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG OncologyAaron R Weiss, Yen-Lin Chen, Thomas J Scharschmidt, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Pageof 23

Showing results (211-220 of 230) with videos related to

Sort By:
Pageof 23
Advanced Materials (Deerfield Beach, Fla.)|September 19, 2025
Terahertz Electronic and Spin Currents in Wafer-Scale Van der Waals Bi<sub>2</sub>Se<sub>3</sub>/WSe<sub>2</sub> Heterostructures and PolymorphsM Mičica, A Wright, S Massabeau, et al.
The Oncologist|July 24, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 StudyRichard F Riedel, Karla V Ballman, Yao Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2011
Quality of life and symptom burden among long-term lung cancer survivorsPing Yang, Andrea L Cheville, Jason A Wampfler, et al.
Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to PembrolizumabEmily Z Keung, Melissa Burgess, Ruth Salazar, et al.
The Lancet. Oncology|October 10, 2017
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialHussein A Tawbi, Melissa Burgess, Vanessa Bolejack, et al.
Mayo Clinic Proceedings|June 26, 2019
Oncolytic Measles Virotherapy and Opposition to Measles VaccinationStephen J Russell, Dusica Babovic-Vuksanovic, Alice Bexon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2023
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG OncologyAaron R Weiss, Yen-Lin Chen, Thomas J Scharschmidt, et al.
The Lancet. Oncology|March 13, 2013
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trialGary K Schwartz, William D Tap, Li-Xuan Qin, et al.
Pageof 23